A prospective study was to evaluate the incidence of erectile dysfunction (ED) in men with metastatic renal cell carcinoma (mRCC) receiving first-line therapy
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Axitinib; Lenvatinib; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 15 Mar 2024 New trial record